The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist

Publisher： John Wiley & Sons Inc

E-ISSN： 1528-1167|56|1|12-27

ISSN： 0013-9580

Source： EPILEPSIA, Vol.56, Iss.1, 2015-01, pp. : 12-27

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel

By  

EPILEPSIA, Vol. 56, Iss. 8, 2015-08 ,pp. : 1252-1263

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacology in translation: the preclinical and early clinical profile of the novel α2/3 functionally selective GABAA receptor positive allosteric modulator PF‐06372865

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 175, Iss. 4, 2018-02 ,pp. : 708-725

John Wiley & Sons Inc

Access to resources Recommend Favorite

First proof of pharmacology in humans of a novel glucagon receptor antisense drug

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 3, 2015-03 ,pp. : 298-306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Profile of Relaxin, a Possible New Drug for Human Use

By  

Current Drug Safety, Vol. 4, Iss. 3, 2009-09 ,pp. : 238-249

Bentham Science Publishers

Access to resources Recommend Favorite

Transporters in Drug Development and Clinical Pharmacology

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 1, 2013-07 ,pp. : 3-9

John Wiley & Sons Inc

Access to resources Recommend Favorite